The company announced a letter of agreement with the Sanquin Blood Supply Foundation, which gives Lev the OK to file for European marketing authorization of C1 to treat the life-threatening attacks associated with HAE, such as inflammation of the larynx, abdomen, face, extremities and urogenital tract. Lev also received authorization from the European Medicines Agency (EMEA) to submit an application for C1 for Community Marketing Authorization through the centralized European registration procedure.